Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4632MR)

This product GTTS-WQ4632MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4632MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14187MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ11212MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ15381MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ13656MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ9917MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ8958MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ4832MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ5624MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP791
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW